erlotinib hydrochloride has been researched along with Colorectal Neoplasms in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (40.28) | 29.6817 |
| 2010's | 38 (52.78) | 24.3611 |
| 2020's | 5 (6.94) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, T; Ishikawa, H; Sato, J; Shikamura, Y; Shino, M; Tanaka, R | 1 |
| Ananda, S; Chandrashekar, S; Dawson, SJ; Desai, J; Gibbs, P; Guinto, J; Hicks, RJ; Koldej, R; Link, E; Markman, B; McArthur, GA; Michael, M; Ritchie, D; Solomon, BJ; Tan, L; Tebbutt, NC; Tie, J; Tran, B; Wong, SQ | 1 |
| Belli, V; Ciardiello, D; Ciardiello, F; De Falco, V; Furia, M; Giunta, EF; Kopetz, S; Martinelli, E; Martini, G; Matrone, N; Morgillo, F; Muddassir, AL; Napolitano, S; Sorokin, A; Troiani, T | 1 |
| Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R | 1 |
| Bekaii-Saab, T; Chen, X; Li, Y; Yang, X; Ye, Y; Zhang, HB; Zhang, Y; Zheng, Y | 1 |
| Gao, L; Li, J; Niu, B; Wu, X; Ye, R; Zhao, Z | 1 |
| Allard, M; Bellesoeur, A; Blanchet, B; Cardoso, E; Rousseau, B | 1 |
| Chen, J; Chen, Q; Liang, C; Liu, Z; Xu, L; Yang, Y; Yang, Z | 1 |
| Berry, T; Boucher, KM; Burt, RW; Byrne, K; Jasperson, K; Jones, D; Kanth, P; Kuwada, SK; Neklason, DW; Pappas, L; Samadder, NJ; Samowitz, W; Sample, D; Smith, L; Tavtigian, SV; Westover, M | 1 |
| Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM | 1 |
| Ebrahimi, P; Kaveh, S; Mozafari, M; Rezapour, A; Sayehmiri, K | 1 |
| Ju, Q; Shao, H; Shi, H; Xu, R; Zhu, J | 1 |
| Colin, DJ; Dormond, O; Nowak-Sliwinska, P; Rausch, M; Zoetemelk, M | 1 |
| Berglund, A; Bergström, D; De Pont Christensen, R; Fernebro, E; Frödin, JE; Garm Spindler, KL; Hagman, H; Jakobsen, A; Johnsson, A; Keldsen, N; Sundberg, J | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Arcilla, M; Benya, R; Bhattacharya, A; Carroll, R; Chen, WP; Chung, J; Gillen, DL; Gonzalez, R; Huang, Z; Lipkin, SM; Meyskens, FL; Mo, A; Morgan, TR; Rodriguez, LM; Rosenberg, DW; Szabo, E; Tucker, C; Wong, V; Zell, JA | 1 |
| Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K | 1 |
| André, T; Aucoin, N; Bonnetain, F; Chibaudel, B; Dauba, J; de Gramont, A; Dupuis, O; Larsen, AK; Latreille, J; Lledo, G; Louvet, C; Mabro, M; Mésange, P; Ramée, JF; Rinaldi, Y; Samson, B; Scheithauer, W; Tournigand, C; Tubiana-Mathieu, N; Vernerey, D; Viret, F | 1 |
| Ciardiello, F | 1 |
| Eng, C; Falchook, GS; Fu, S; Garrett, C; George, GC; Hess, K; Hong, DS; Janku, F; Karp, D; Kopetz, S; Kurzrock, R; Liu, X; Meric-Bernstam, F; Naing, A; Overman, MJ; Piha-Paul, SA; Raghav, K; Subbiah, V; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Albertsson, M; Berglund, Å; Fernebro, E; Frödin, JE; Hagman, H; Johnsson, A; Sundberg, J; Vestermark, LW | 1 |
| Cao, C; Chen, J; Gong, Y; Kuang, M; Tang, C; Wu, P; Xu, W | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Breadner, D; Kerr, IG; Klimo, P; Kocha, W; MacKenzie, MJ; Malpage, AS; O'Connell, A; Sanatani, M; Soulieres, D; Stitt, L; Vincent, MD; Welch, SA; Whiston, F | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Bijnsdorp, IV; Fukushima, M; Gokoel, S; Kruyt, FA; Peters, GJ; Smid, K | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Wörmann, B | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Azad, A; Chong, G; Dobrovic, A; Fluck, K; Gebski, V; Johns, TG; Mariadason, JM; Pavlakis, N; Price, TJ; Salemi, R; Scott, AM; Skrinos, E; Tebbutt, NC; Weickhardt, AJ | 1 |
| Bellail, AC; Gao, S; Hao, C; Li, B; Liu, T; Wei, F | 1 |
| Lo, RS | 1 |
| Molina, JJ; Molina-Prat, N; Morral, M; Quintana, R; Saint-Jean, A; Sainz de la Maza, M; Torras, J | 1 |
| Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G | 1 |
| Cohen, RB | 1 |
| Lorusso, PM | 1 |
| Adenis, A; Peyrat, JP | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Lenz, HJ; Vallbohmer, D | 1 |
| Ganti, AK; Potti, A | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Lawrence, TS; Nyati, MK | 1 |
| Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX | 1 |
| Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK | 1 |
| Adames, V; Chen, J; Fritzky, L; Higgins, B; Kolinsky, K; Linn, M; Mehta, N; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J | 1 |
| Barr, S; Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Sennello, R; Thompson, S; Young, D | 1 |
| Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Buchanan, FG; DuBois, RN; Holla, V; Katkuri, S; Matta, P | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Ng, K; Zhu, AX | 1 |
20 review(s) available for erlotinib hydrochloride and Colorectal Neoplasms
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment | 2020 |
Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Humans; Randomized Controlled Trials as Topic | 2019 |
Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Disease-Free Survival; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2016 |
Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Survival Analysis | 2017 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Inhibitors of epidermal growth factor receptor and colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2004 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor as a target for chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines | 2008 |
25 trial(s) available for erlotinib hydrochloride and Colorectal Neoplasms
| Article | Year |
|---|---|
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Topics: Colonic Neoplasms; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Rectal Neoplasms; Sulfonamides; Vemurafenib | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2017 |
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Sulindac; Treatment Outcome | 2018 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.
Topics: Aberrant Crypt Foci; Case-Control Studies; Colorectal Neoplasms; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Rectum; Signal Transduction | 2015 |
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged | 2015 |
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Bevacizumab; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Liver Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Tumor Burden | 2017 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Treatment Outcome | 2012 |
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome | 2013 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2007 |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quinazolines | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
28 other study(ies) available for erlotinib hydrochloride and Colorectal Neoplasms
| Article | Year |
|---|---|
Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs.
Topics: Acne Vulgaris; Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Panitumumab; Quality of Life; Receptors, Growth Factor; Retrospective Studies | 2022 |
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Cell Line, Tumor; Colorectal Neoplasms; Diphenylamine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.
Topics: Adenocarcinoma; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors | 2020 |
[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].
Topics: Antineoplastic Agents; Bayes Theorem; Bevacizumab; Colorectal Neoplasms; Drug Monitoring; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Liver; Neoplasms; Phenylurea Compounds; Pyridines | 2017 |
Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy.
Topics: Administration, Oral; Animals; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterografts; Humans; Immunotherapy; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Permeability; Tumor Microenvironment | 2017 |
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Cell Culture Techniques; Coculture Techniques; Colorectal Neoplasms; Drug Evaluation, Preclinical; Endothelial Cells; Erlotinib Hydrochloride; Fibroblasts; Fluorouracil; HCT116 Cells; Humans; Phenylurea Compounds; Pyridines; Reproducibility of Results; Spheroids, Cellular; Tumor Microenvironment | 2019 |
Maintenance therapy for metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Humans; Maintenance Chemotherapy; Male | 2015 |
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins p21(ras); Retreatment | 2015 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Topics: Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Genes, ras; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Thymidylate Synthase; Trifluridine | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Melanoma; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Transplantation, Heterologous; Vemurafenib | 2012 |
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Corneal Perforation; Ectropion; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratoplasty, Penetrating; Lung Neoplasms; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Visual Acuity | 2012 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Topics: Colon; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines | 2005 |
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Transplantation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous | 2007 |
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.
Topics: Biomarkers, Tumor; Cadherins; Cell Adhesion; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Mesoderm; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis; Vimentin | 2007 |
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Intestinal Polyps; Intestine, Small; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Prostaglandins; Pyrazoles; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |